A new retrospective study published in JAMA identified that tuberculosis and certain fungal infections in the lungs could hamper the efficient detection of lung cancer by FDG-PET imaging.
A test used to diagnose lung cancer may not be as reliable in geographic regions where certain lung infections are more common, a new analysis says.
One noninvasive way of detecting lung cancer is through the use of what's known as functional imaging. For lung cancer, a specific type of functional imaging called FDG-PET is used, according to the study authors.
Cancerous tumors generally look different on FDG-PET images than do parts of the lungs that don't have cancer, according to background information in the study. But, it can be difficult to tell the difference between lung cancer and some lung infections, according to the study.
Lung conditions that might affect the accuracy of the functional imaging tests include tuberculosis and fungal infections, the study authors said.
Geographic regions in the new analysis where tuberculosis is common include China, Japan and South Africa. Areas where fungal lung infections occur frequently include the Mississippi, Missouri and Ohio river valley regions, as well as the U.S. Southwest, and Ontario, Canada, according to the analysis.
The analysis looked at the results of 70 studies.
Report on MedlinePlus: http://1.usa.gov/Yc90VQ
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen